Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)
about
Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease.Nine-year experience in Gaucher disease diagnosis at the Spanish reference center Fundación Jiménez DíazA new framework for evaluating the health impacts of treatment for Gaucher disease type 1.Glucosylsphingosine is a key biomarker of Gaucher disease.
P2860
Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Evaluation of disease burden a ...... severity scoring system (DS3)
@ast
Evaluation of disease burden a ...... severity scoring system (DS3)
@en
type
label
Evaluation of disease burden a ...... severity scoring system (DS3)
@ast
Evaluation of disease burden a ...... severity scoring system (DS3)
@en
prefLabel
Evaluation of disease burden a ...... severity scoring system (DS3)
@ast
Evaluation of disease burden a ...... severity scoring system (DS3)
@en
P2093
P2860
P1476
Evaluation of disease burden a ...... severity scoring system (DS3)
@en
P2093
Barry E Rosenbloom
Dominick Amato
Neal J Weinreb
Suma P Shankar
P2860
P2888
P356
10.1186/S13023-015-0280-3
P577
2015-05-22T00:00:00Z
P5875
P6179
1017924960